Impact of the N-Terminal Amino Acid on the Formation of Pyrazines from Peptides in Maillard Model Systems
作者:Fien Van Lancker、An Adams、Norbert De Kimpe
DOI:10.1021/jf301315b
日期:2012.5.9
peptide C-terminal amino acid was investigated, this study focused on the influence of the peptide N-terminal amino acid on the production of pyrazines in model reactions of glucose, methylglyoxal, or glyoxal. Nine different dipeptides and three tripeptides were selected. It was shown that the structure of the N-terminal amino acid is determinative for the overall pyrazine production. Especially, the production
[EN] SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES<br/>[FR] AMINES BICYCLIQUES SUBSTITUÉES POUR LE TRAITEMENT DU DIABÈTE
申请人:MERCK SHARP & DOHME
公开号:WO2010056717A1
公开(公告)日:2010-05-20
Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.
Formation of Pyrazines in Maillard Model Systems of Lysine-Containing Dipeptides
作者:Fien Van Lancker、An Adams、Norbert De Kimpe
DOI:10.1021/jf903898t
日期:2010.2.24
respectively. Generally, the pyrazines were produced more in the case of dipeptides as compared to free amino acids. For reactions with glucose and methylglyoxal, this difference was mainly caused by the large amounts of 2,5(6)-dimethylpyrazine and trimethylpyrazine produced from the reactions with dipeptides. For reactions with glyoxal, the difference in pyrazine production was rather small and mostly unsubstituted
A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I):
[wherein, R
1
represents optionally substituted lower alkyl or the like; R
2
represents optionally substituted cycloalkyl or the like; R
3
represents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.
This invention provides a process for preparing monoacylpyrazines which involves coreacting an aldehyde (R-CHO) and a pyrazine compound corresponding to the formula:
where R1, R2 and R3 are substituents selected from hydrogen and alkyl groups, and R1 and R when taken together with connecting elements may form an alicyclic or aromatic structure, and R in the aldehyde compound is selected from aliphatic, alicyclic and aromatic groups under free radical conditions in a heterogeneous reaction medium consisting of an organic phase and an aqueous phase. The compounds prepared have the formula:
where R, R', R2 and R3 are as previously defined, which is then recovered.
本发明提供了一种制备单酰基吡嗪的工艺,该工艺包括在由有机相和水相组成的异相反应介质中,在自由基条件下,将醛(R-CHO)和式中所对应的吡嗪化合物进行共反应: 式中 R1、R2 和 R3 是选自氢和烷基的取代基,R1 和 R 与连接元素结合在一起时可形成脂环族或芳香族结构,醛化合物中的 R 选自脂肪族、脂环族和芳香族基团。 所制备的化合物具有式: 式中 R、R'、R2 和 R3 如前定义,然后将其回收。